Goncagul Akdag, Sedat Yildirim, Akif Dogan, Zeynep Yuksel Yasar, Hamit Bal, Oguzcan Kinikoglu, Sila Oksuz, Ugur Ozkerim, Salih Tunbekici, Hacer Sahika Yildiz, Ezgi Turkoglu, Ozkan Alan, Sermin Coban Kokten, Deniz Isik, Ozlem Nuray Sever, Hatice Odabas, Mahmut Emre Yildirim, Nedim Turan
INTRODUCTION: Neoadjuvant chemotherapy (NAC) is extensively employed in breast cancer (BC), primarily for aggressive subtypes like triple-negative and human epidermal growth factor receptor 2 (HER2) positive BC, and in estrogen receptor-positive (ER+)/ HER2- BC with high-risk features. In ER+/HER2- breast cancer, pathological complet rates are much lower (<10%), while axillary dissection rates are higher. This study focuses on hormone receptor positive (HR+)/HER2- BC patients undergoing NAC, examining its impact on pathological complete response (pCR) rates, with specific attention to tumor Ki67 and ER status...
February 16, 2024: Chemotherapy